Last updated on October 2019

A Study to Evaluate the Use of Apremilast in Patients With Psoriatic Arthritis Na ve to Biological Treatment


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: PSORIATIC ARTHRITIS
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Men and women older than 18 years.
  • Patients diagnosed with psoriatic arthritis according to the CASPAR criteria*.
  • Patients who, following the routine clinical practice, initiated treatment with apremilast 6 months (4 weeks) before their inclusion in the study.
  • Patients naive to biologic treatments.

Exclusion Criteria:

  • Patients who reject to sign the informed consent.
  • Patients enrolled in a clinical trial within the 4 weeks preceding the baseline visit or for the duration of apremilast treatment.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.